Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S. Panageas, Philip Wong, Xinqi Wu, Jarushka Naidoo, David B. Page, Jedd D. Wolchok, F. Stephen Hodi

Research output: Contribution to journalArticle

Abstract

Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated for association with clinical benefit in ipilimumab-treated patients. Sera were collected from 176 patients treated at 3 (n = 98) or 10 mg/kg (n = 68). The VEGF levels before treatment and at induction completion (week 12) were analyzed using the Meso Scale Discovery kit. The association of the levels of VEGF with clinical responses and OS were assessed using the Fisher exact and Kaplan-Meier log-rank tests. VEGF as a continuous variable was associated with OS (P = 0.002). Using 43 pg/mL as the cutoff pretreatment VEGF value defined by maximally selected log-rank statistics, pretreatment VEGF values correlated with clinical benefit at week 24 (P = 0.019; 159 patients evaluable). Pretreatment VEGF ≥ 43 pg/mL was associated with decreased OS (median OS 6.6 vs. 12.9 months, P = 0.006; 7.4 vs. 14.3 months, P = 0.037 for 3 mg/kg; and 6.2 vs. 10.9 months, P = 0.048 for 10 mg/kg). There was no correlation between VEGF changes and clinical outcome. Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)127-132
Number of pages6
JournalCancer immunology research
Volume2
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Melanoma
Survival
Serum
Immune Evasion
ipilimumab
Immune Sera
Biomarkers
Antigens
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. / Yuan, Jianda; Zhou, Jun; Dong, Zhiwan; Tandon, Sapna; Kuk, Deborah; Panageas, Katherine S.; Wong, Philip; Wu, Xinqi; Naidoo, Jarushka; Page, David B.; Wolchok, Jedd D.; Hodi, F. Stephen.

In: Cancer immunology research, Vol. 2, No. 2, 01.02.2014, p. 127-132.

Research output: Contribution to journalArticle

Yuan, J, Zhou, J, Dong, Z, Tandon, S, Kuk, D, Panageas, KS, Wong, P, Wu, X, Naidoo, J, Page, DB, Wolchok, JD & Hodi, FS 2014, 'Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab', Cancer immunology research, vol. 2, no. 2, pp. 127-132. https://doi.org/10.1158/2326-6066.CIR-13-0163
Yuan, Jianda ; Zhou, Jun ; Dong, Zhiwan ; Tandon, Sapna ; Kuk, Deborah ; Panageas, Katherine S. ; Wong, Philip ; Wu, Xinqi ; Naidoo, Jarushka ; Page, David B. ; Wolchok, Jedd D. ; Hodi, F. Stephen. / Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. In: Cancer immunology research. 2014 ; Vol. 2, No. 2. pp. 127-132.
@article{a020383335464885ba086143372b7e8a,
title = "Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab",
abstract = "Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated for association with clinical benefit in ipilimumab-treated patients. Sera were collected from 176 patients treated at 3 (n = 98) or 10 mg/kg (n = 68). The VEGF levels before treatment and at induction completion (week 12) were analyzed using the Meso Scale Discovery kit. The association of the levels of VEGF with clinical responses and OS were assessed using the Fisher exact and Kaplan-Meier log-rank tests. VEGF as a continuous variable was associated with OS (P = 0.002). Using 43 pg/mL as the cutoff pretreatment VEGF value defined by maximally selected log-rank statistics, pretreatment VEGF values correlated with clinical benefit at week 24 (P = 0.019; 159 patients evaluable). Pretreatment VEGF ≥ 43 pg/mL was associated with decreased OS (median OS 6.6 vs. 12.9 months, P = 0.006; 7.4 vs. 14.3 months, P = 0.037 for 3 mg/kg; and 6.2 vs. 10.9 months, P = 0.048 for 10 mg/kg). There was no correlation between VEGF changes and clinical outcome. Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade.",
author = "Jianda Yuan and Jun Zhou and Zhiwan Dong and Sapna Tandon and Deborah Kuk and Panageas, {Katherine S.} and Philip Wong and Xinqi Wu and Jarushka Naidoo and Page, {David B.} and Wolchok, {Jedd D.} and Hodi, {F. Stephen}",
year = "2014",
month = "2",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0163",
language = "English (US)",
volume = "2",
pages = "127--132",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

AU - Yuan, Jianda

AU - Zhou, Jun

AU - Dong, Zhiwan

AU - Tandon, Sapna

AU - Kuk, Deborah

AU - Panageas, Katherine S.

AU - Wong, Philip

AU - Wu, Xinqi

AU - Naidoo, Jarushka

AU - Page, David B.

AU - Wolchok, Jedd D.

AU - Hodi, F. Stephen

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated for association with clinical benefit in ipilimumab-treated patients. Sera were collected from 176 patients treated at 3 (n = 98) or 10 mg/kg (n = 68). The VEGF levels before treatment and at induction completion (week 12) were analyzed using the Meso Scale Discovery kit. The association of the levels of VEGF with clinical responses and OS were assessed using the Fisher exact and Kaplan-Meier log-rank tests. VEGF as a continuous variable was associated with OS (P = 0.002). Using 43 pg/mL as the cutoff pretreatment VEGF value defined by maximally selected log-rank statistics, pretreatment VEGF values correlated with clinical benefit at week 24 (P = 0.019; 159 patients evaluable). Pretreatment VEGF ≥ 43 pg/mL was associated with decreased OS (median OS 6.6 vs. 12.9 months, P = 0.006; 7.4 vs. 14.3 months, P = 0.037 for 3 mg/kg; and 6.2 vs. 10.9 months, P = 0.048 for 10 mg/kg). There was no correlation between VEGF changes and clinical outcome. Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade.

AB - Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated for association with clinical benefit in ipilimumab-treated patients. Sera were collected from 176 patients treated at 3 (n = 98) or 10 mg/kg (n = 68). The VEGF levels before treatment and at induction completion (week 12) were analyzed using the Meso Scale Discovery kit. The association of the levels of VEGF with clinical responses and OS were assessed using the Fisher exact and Kaplan-Meier log-rank tests. VEGF as a continuous variable was associated with OS (P = 0.002). Using 43 pg/mL as the cutoff pretreatment VEGF value defined by maximally selected log-rank statistics, pretreatment VEGF values correlated with clinical benefit at week 24 (P = 0.019; 159 patients evaluable). Pretreatment VEGF ≥ 43 pg/mL was associated with decreased OS (median OS 6.6 vs. 12.9 months, P = 0.006; 7.4 vs. 14.3 months, P = 0.037 for 3 mg/kg; and 6.2 vs. 10.9 months, P = 0.048 for 10 mg/kg). There was no correlation between VEGF changes and clinical outcome. Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=84996525854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996525854&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0163

DO - 10.1158/2326-6066.CIR-13-0163

M3 - Article

VL - 2

SP - 127

EP - 132

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 2

ER -